Last reviewed · How we verify
NCT06761742
Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests
trial in Renal Tumors in 1,922 participants. Completed in 1 December 2024.
1 December 2024
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,922 |
| Start date | 1 January 2024 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across China |
Conditions studied
- Renal Tumors — all drugs for Renal Tumors →
Sponsor
RenJi Hospital
Who can join
Eligibility, any sex, with Renal Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multi-center retrospective study aims to develop a multimodal artificial intelligence diagnostic model using preoperative contrast-enhanced CT images and routine laboratory parameters from patients with renal tumors. The model is designed to assist clinicians in accurately predicting the pathological subtypes of renal tumors preoperatively, enabling detailed diagnoses and advancing precision medicine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06761742
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Tumors
Currently open trials in the same condition.
- NCT06868927 — Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform · recruiting
- NCT06868186 — A Multicenter Study of RUS NE · NA · recruiting
- NCT06954571 — Imaging-Guided Classification for Endophytic Renal Tumors: PN Strategies & Outcomes · active not recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06761742 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06761742.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing